Pomalidomide CAS 19171-19-8

1. Pomalidomide is a third-generation immunomodulatory drug (IMiD) and derivative of thalidomide, primarily used as an anti-angiogenic and antineoplastic agent for the treatment of relapsed and refractory multiple myeloma (RRMM) in adult patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor .
2. Pomalidomide CAS 19171-19-8 is approved by the FDA in combination with dexamethasone for multiple myeloma and for the treatment of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in HIV-negative patients .
3. Pomalidomide functions by binding to the target protein cereblon (CRBN), forming a complex that leads to the degradation of key transcription factors such as Ikaros and Aiolos, resulting in direct anti-myeloma activity, T-cell activation, natural killer (NK) cell enhancement, and inhibition of tumor necrosis factor-alpha (TNF-α) production .
4. Pomalidomide CAS 19171-19-8 has also demonstrated substantial activity in phase II and III clinical trials for other conditions including systemic light chain amyloidosis, POEMS syndrome, myelofibrosis, and primary central nervous system lymphoma, with ongoing investigations for use in solid tumors .

1. Pomalidomide must be stored in a tightly sealed container in a cool, dry, and well-ventilated environment at refrigerated temperatures (0-10°C), protected from light and moisture, as it is heat sensitive .
2. For long-term stability, Pomalidomide powder is stable for up to 3 years at -20°C or 2 years at 4°C; solutions should be stored at -80°C for up to 6 months or -20°C for up to 1 month, avoiding repeated freeze-thaw cycles .
3. Pomalidomide CAS 19171-19-8 is classified with GHS signal word "Warning" and hazard statement H361 (Suspected of damaging fertility or the unborn child); personnel who are or may become pregnant should NOT handle this medicine, and it must be stored locked up away from children .
4. Pomalidomide is subject to the Pomalyst REMS (Risk Evaluation and Mitigation Strategy) program, requiring prescribers, pharmacies, and patients to be registered; patients must use effective birth control during treatment and for an extended period after the last dose due to teratogenic risks .

1. Isolate the spill area, ensure adequate ventilation, and wear full personal protective equipment including chemical-resistant gloves, safety goggles, and a suitable dust respirator when Pomalidomide is released .
2. Collect Pomalidomide CAS 19171-19-8 by sweeping or vacuuming without creating dust using non-sparking tools; absorb solutions with finely-powdered liquid-binding materials such as diatomite or universal binders .
3. Avoid creating dust clouds during cleanup to prevent respiratory exposure; decontaminate surfaces and equipment by scrubbing with alcohol, and prevent Pomalidomide from entering drains or water courses .
4. Dispose of collected material as hazardous waste according to local, state, and federal environmental regulations; Pomalidomide is considered non-hazardous for transport (DOT, IATA, IMDG) but requires proper waste management .

1. Pomalidomide is not classified as highly flammable but may decompose under fire conditions, emitting toxic and irritant fumes including carbon monoxide, carbon dioxide, and nitrogen oxides (NOx) .
2. Use Pomalidomide CAS 19171-19-8 water spray, dry chemical powder, carbon dioxide, or alcohol-resistant foam to extinguish fires involving Pomalidomide .
3. Firefighters should wear self-contained breathing apparatus in pressure-demand, MSHA/NIOSH approved, and full protective gear when handling burning Pomalidomide due to hazardous decomposition gases generated by thermal decomposition .
4. During combustion, Pomalidomide may emit irritant and toxic fumes; contain fire runoff to prevent environmental contamination and avoid release into waterways .